Elsevier

Cytokine

Volume 60, Issue 1, October 2012, Pages 1-12
Cytokine

Review Article
Monocyte Chemoattractant Protein 1 (MCP-1) in obesity and diabetes

https://doi.org/10.1016/j.cyto.2012.06.018Get rights and content

Abstract

Monocyte Chemoattractant Protein-1 (MCP-1) is the first discovered and most extensively studied CC chemokine, and the amount of studies on its role in the etiologies of obesity- and diabetes-related diseases have increased exponentially during the past two decades. This review attempted to provide a panoramic perspective of the history, regulatory mechanisms, functions, and therapeutic strategies of this chemokine. The highlights of this review include the roles of MCP-1 in the development of obesity, diabetes, cardiovascular diseases, insulitis, diabetic nephropathy, and diabetic retinopathy. Therapies that specifically or non-specifically inhibit MCP-1 overproduction have been summarized.

Highlights

► Historic perspectives of the pioneer studies on MCP-1. ► Role of MCP-1 in obesity-related metabolic syndrome. ► Role of MCP-1 in type 2 diabetes and diabetic complications. ► Treatments on MCP-1 over-production and inhibition of MCP-1 signaling.

Section snippets

Historical perspectives of Monocyte Chemoattractant Protein-1

1989 witnessed the birth of Monocyte Chemoattractant Protein-1 (MCP-1) into the light of scientific investigation at the National Cancer Institute, Maryland, USA. This protein was initially identified from the conditioned media of human myelomonocytic cell line as the monocyte chemotactic factor (MCF) [1]. It was further named as monocyte chemotactic and activating factor (MCAF), which was found to be rapidly produced in normal human dermal fibroblasts in response to the stimuli of

Transcriptional regulation of MCP-1

Expression of MCP-1 is ubiquitous in various cell types and is upregulated by a wide variety of stimuli. The list of MCP-1-producing cell types grew rapidly after the aforementioned pioneer studies in 1989 [13], [14], [15], [16], [17], [18]. A summary of MCP-1-producing cell types and stimuli can be found in Table 3 in a review by Van Collie et al. [8]. In addition, adipocytes have been recognized as an important source of MCP-1[19], [20].

Human MCP-1 gene consists of three exons of 145, 118 and

MCP-1 and obesity

A Pubmed keyword-guided literature search showed a linear increase of the number of publications related to “MCP-1” during the period of 1989–2010, while an exponential increase of the percentages of these publications pertaining to either “obesity” or “diabetes”, implicating a rapidly growing interest in the pathological role of this chemokine under obese and diabetic conditions.

Obesity is a result of expansion in both number and size of adipocytes. The gene expression of CC chemokines and

MCP-1 and type 2 diabetes

Type 2 diabetes comprises 95% of diabetic cases and its etiology is closely related to obesity and insulin resistance. Circulating MCP-1 has been found significantly increased in patients with type 2 diabetes [80], [81], [82], [83], [84].

A common A/G polymorphism located at position -2518 in the distal regulatory region regulates MCP-1 expression [85]. In a large cohort of German Caucasians, the MCP-1 G-2518 gene variant was found significantly and negatively correlated with plasma MCP-1 levels

Diabetic complication – cardiovascular disease

Diabetes is associated with accelerated rates of atherosclerosis. MCP-1 attracts monocytes to the inflammatory sites of vascular subendothelial space, initiating migration of monocytes into the arterial wall to form excessive macrophage-derived foam cells. Large population-based studies showed significant correlation between circulating MCP-1 and other traditional risk factor for atherosclerosis, such as serum high-sensitivity C-reactive protein (hsCRP), plasma fibrinogen, and combined carotid

Diabetic nephropathy

Diabetic nephropathy is a kidney disease that develops gradually over a period of 15–20 years after the onset of diabetes, affects ∼40% of diabetic patients, and is the primary cause of dialysis [138]. The pathologic abnormalities related to this diabetic complication include mesangial expansion, glomerular basement membrane thickening, and glomerular sclerosis [139]. The significant role of MCP-1 in the development of diabetic nephropathy has been implicated by several studies using MCP-1

Diabetic retinopathy

Diabetic retinopathy is a diabetic complication that can cause blindness. The incidence of this disease is approximately 60% after 10 years with type 1 diabetes and after 20 years with type 2 diabetes [192]. Reportedly myofibroblasts and vascular endothelial cells are the major cell types expressing MCP-1 in epiretinal membranes (ERMs), caused by changes in the vitreous humor in diabetic eyes [193]. When ERM were collected from patients with proliferative diabetic retinopathy (PDR), MCP-1 mRNA

Insulitis and islet transplantation

Insulitis is an inflammatory status in pancreatic islets, signified by mononuclear cell infiltration and destruction of insulin-producing cells. It is a causative factor of insulin dependence in both type 1 and type 2 diabetes [205]. In non-obese diabetic (NOD) mice, MCP-1 mRNA expression was found to increase with age and peak at the early phases of insulitis, and therefore the production of MCP-1 by cells could contribute to the recruitment of mononuclear cells into pancreatic islets [29].

MCP-1-specific treatments

Due to the pathological significance of MCP-1, efforts have been exerted to specifically target the signaling pathway of this chemokine. Several studies have attempted to decrease MCP-1 level in the circulation or block CCR2 activity by antibody administration. Such a neutralization of MCP-1 ameliorated glomerular crescent formation and development of interstitial fibrosis in mice [211]. However, when a MCP-1 monoclonal antibody was tested in patients with rheumatoid arthritis, the treatment

Acknowledgements

This study was made possible by Grant numbers R21 AT003874 and R21 AT005139 from NCCAM and ORWH, 5G12RR003061 (RCMI/BRIDGES), U54RR022762 (RTRN Small Grant Program), and 5P20RR016467 (INBRE II) from NCRR. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the funding agencies or the NIH.

References (225)

  • A. Ueda et al.

    Transcriptional regulation of the human monocyte chemoattractant protein-1 gene

    J Biol Chem

    (1997)
  • S. Hanazawa et al.

    Tumor necrosis factor-alpha induces expression of monocyte chemoattractant JE via fos and jun genes in clonal osteoblastic MC3T3-E1 cells

    J Biol Chem

    (1993)
  • D. Ping et al.

    TNF regulates the in vivo occupancy of both distal and proximal regulatory regions of the murine monocyte chemoattractant protein-1 (MCP-1/JE) gene

    Immunity

    (1996)
  • J. Yu et al.

    Conditioned medium from hypoxia-treated adipocytes renders muscle cells insulin resistant

    Eur J Cell Biol

    (2011)
  • L. Dhawan et al.

    A novel role for the glucocorticoid receptor in the regulation of monocyte chemoattractant protein-1 mRNA stability

    J Biol Chem

    (2007)
  • Y.H. Lee et al.

    Visceral adiposity and the severity of coronary artery disease in middle-aged subjects with normal waist circumference and its relation with lipocalin-2 and MCP-1

    Atherosclerosis

    (2010)
  • K.R. Kelly et al.

    A low-glycemic index diet and exercise intervention reduces TNF(alpha) in isolated mononuclear cells of older, obese adults

    J Nutr

    (2011)
  • C.W. Younce et al.

    MCP-1 (monocyte chemotactic protein-1)-induced protein, a recently identified zinc finger protein, induces adipogenesis in 3T3-L1 pre-adipocytes without peroxisome proliferator-activated receptor gamma

    J Biol Chem

    (2009)
  • R. Salcedo et al.

    Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression

    Blood

    (2000)
  • J.K. Higa et al.

    Bamboo extract reduces interleukin 6 (IL-6) overproduction under lipotoxic conditions through inhibiting the activation of NFkappaB and AP-1 pathways

    Cytokine

    (2011)
  • M. Sugimoto et al.

    Mulberry leaf ameliorates the expression profile of adipocytokines by inhibiting oxidative stress in white adipose tissue in db/db mice

    Atherosclerosis

    (2009)
  • M.S. Kang et al.

    Dehydroabietic acid, a phytochemical, acts as ligand for PPARs in macrophages and adipocytes to regulate inflammation

    Biochem Biophys Res Commun

    (2008)
  • J.H. Kang et al.

    Capsaicin, a spicy component of hot peppers, modulates adipokine gene expression and protein release from obese-mouse adipose tissues and isolated adipocytes, and suppresses the inflammatory responses of adipose tissue macrophages

    FEBS Lett

    (2007)
  • H.M. Woo et al.

    Active spice-derived components can inhibit inflammatory responses of adipose tissue in obesity by suppressing inflammatory actions of macrophages and release of monocyte chemoattractant protein-1 from adipocytes

    Life Sci

    (2007)
  • M.R. Chacón et al.

    Grape-seed procyanidins modulate inflammation on human differentiated adipocytes in vitro

    Cytokine

    (2009)
  • J. Zhu et al.

    Anti-inflammatory effect of resveratrol on TNF-alpha-induced MCP-1 expression in adipocytes

    Biochem Biophys Res Commun

    (2008)
  • S.K. Jain et al.

    L-cysteine supplementation lowers blood glucose, glycated hemoglobin, CRP, MCP-1, and oxidative stress and inhibits NF-kappaB activation in the livers of Zucker diabetic rats

    Free Radic Biol Med

    (2009)
  • U. Kintscher et al.

    Peroxisome proliferator-activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytes

    Eur J Pharmacol

    (2000)
  • K. Takebayashi et al.

    The effect of low-dose atorvastatin on circulating monocyte chemoattractant protein-1 in patients with type 2 diabetes complicated by hyperlipidemia

    Metabolism

    (2005)
  • K. Sonoki et al.

    Dilazep and fenofibric acid inhibit MCP-1 mRNA expression in glycoxidized LDL-stimulated human endothelial cells

    Eur J Pharmacol

    (2003)
  • M.H. Lee et al.

    Angiotensin receptor blockers improve insulin resistance in type 2 diabetic rats by modulating adipose tissue

    Kidney Int

    (2008)
  • V. Bláha et al.

    Effect of atorvastatin on soluble CD14, CD40 Ligand, sE- and sP-selectins and MCP-1 in patients with type 2 diabetes mellitus: relationship to cholesterol turnover

    Pharmacol Res

    (2006)
  • B.H. Rovin et al.

    A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression

    Biochem Bioph Res Comm

    (1999)
  • Y. Jing et al.

    Monocyte chemoattractant protein 1–2518 A/G polymorphism and susceptibility to type 2 diabetes in a Chinese population

    Clin Chim Acta

    (2011)
  • N. Katakami et al.

    Monocyte chemoattractant protein-1 (MCP-1) gene polymorphism as a potential risk factor for diabetic retinopathy in Japanese patients with type 2 diabetes

    Diabetes Res Clin Pract

    (2010)
  • S. Yuasa et al.

    MCP-1 gene A-2518G polymorphism and carotid artery atherosclerosis in patients with type 2 diabetes

    Diabetes Res Clin Pract

    (2009)
  • R. Deo et al.

    Association among plasma levels of monocyte chemoattractant protein-1, traditional cardiovascular risk factors, and subclinical atherosclerosis

    J Am Coll Cardiol

    (2004)
  • P. Tretjakovs et al.

    Relation of inflammatory chemokines to insulin resistance and hypoadiponectinemia in coronary artery disease patients

    Eur J Intern Med

    (2009)
  • K. Takebayashi et al.

    Association between circulating monocyte chemoattractant protein-1 and urinary albumin excretion in nonobese Type 2 diabetic patients

    J Diabetes Complicat

    (2006)
  • J.A. de Lemos et al.

    J Am Coll Cardiol

    (2007)
  • K. Matsushima et al.

    Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line

    J Exp Med

    (1989)
  • T. Yoshimura et al.

    Purification and amino acid analysis of two human glioma-derived monocyte chemoattractants

    J Exp Med

    (1989)
  • T. Yoshimura et al.

    Purification and amino acid analysis of two human monocyte chemoattractants produced by phytohemagglutinin-stimulated human blood mononuclear leukocytes

    J Immunol

    (1989)
  • E.A. Robinson et al.

    Complete amino acid sequence of a human monocyte chemoattractant, a putative mediator of cellular immune reactions

    Proc Natl Acad Sci USA

    (1989)
  • P. Proost et al.

    Posttranslational modifications affect the activity of the human monocyte chemotactic proteins MCP-1 and MCP-2: identification of MCP-2(6–76) as a natural chemokine inhibitor

    J Immunol

    (1998)
  • I.F. Charo et al.

    Molecular cloning and functional expression of two monocyte chemoattractant protein 1 receptors reveals alternative splicing of the carboxyl-terminal tails

    Proc Natl Acad Sci USA

    (1994)
  • A. Sica et al.

    Monocyte chemotactic and activating factor gene expression induced in endothelial cells by IL-1 and tumor necrosis factor

    J Immunol

    (1990)
  • S.D. Cushing et al.

    Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells

    Proc Natl Acad Sci USA

    (1990)
  • P. Sartipy et al.

    Monocyte chemoattractant protein 1 in obesity and insulin resistance

    Proc Natl Acad Sci USA

    (2003)
  • J. Huber et al.

    CC chemokine and CC chemokine receptor profiles in visceral and subcutaneous adipose tissue are altered in human obesity

    J Clin Endocrinol Metab

    (2008)
  • Cited by (326)

    View all citing articles on Scopus
    View full text